The RISE Above Overdose trial explores the impact of remote and in-person treatment settings on participants' ability to attend study sessions and adhere to treatment and study protocols. Participants will be recruited based on DSM-5 opioid use and/or stimulant use disorder(s) criteria and provided with a naloxone kit and administration training, while meeting with study staff for a total of 6 sessions in a 4-month period. The trial's experimental core is the 2-stage randomization process. Eligible participants are first randomized to attend either a remote or in-person intake session and then randomized again at intake to determine whether their remaining 5 sessions will take place remotely or in-person. The resultant 4-cell design allows for a balanced and rigorous assessment of the differences between participant accrual, retention, treatment adherence, and biospecimen collection in remote versus in-person settings.